<DOC>
	<DOCNO>NCT01678807</DOCNO>
	<brief_summary>The purpose study evaluate safety two dos ( 6 Development Units [ DU ] 12 DU ) MK-8237 sublingual tablet compare Placebo adolescent house dust mite-induced allergic rhinitis/rhinoconjunctivitis . The primary hypothesis least one dose MK-8237 sublingual tablet safe well-tolerated adolescent house dust mite-induced allergic rhinitis/rhinoconjunctivitis .</brief_summary>
	<brief_title>Safety Study MK-8237 Treatment House-Dust-Mite Allergic Adolescents ( MK-8237-008 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>History physiciandiagnosed allergic rhinitis/rhinoconjunctivitis house dust least 6 month duration ( without asthma ) History control asthma prior 1 month participant asthma , define exceed 2 day symptom per week ; 2 day albuterol/short act betaagonist [ SABA ] use per week ; waken twice month night due asthma symptom Agrees remain abstinent use ( partner use ) 2 acceptable method birth control screen duration study Unable meet medication washout requirement History chronic urticaria and/or chronic angioedema within prior 2 year History anaphylaxis cardiorespiratory symptom prior immunotherapy due unknown cause inhalant allergen Unstable , uncontrolled severe asthma , experience lifethreatening asthma attack occurrence clinical deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic corticosteroid ( allow SABAs ) time within prior 3 month History chronic sinusitis within prior 2 year Pregnant breastfeeding , expect conceive within project duration study Known history allergy , hypersensitivity intolerance investigational medicinal product except Dermatophagoides pteronyssinus ( D. pteronyssinus ) and/or Dermatophagoides farina ( D. farina ) selfinjectable epinephrine Business personal relationship investigational site personnel Sponsor directly involve conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>